Saturday 17 October 2026
Export CELU’s income statement to Excel — free account
Celularity, Inc.
CELU Healthcare Biotechnology
Celularity, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $26.6 million, down 51.0% from fiscal 2024. In the quarter to March 2026, revenue fell 66.3%, EPS grew 103.6%, free cash flow grew 148.4% and total debt fell 4.73%, each against the same quarter a year earlier.
1.25
0.08
−6.02%
Follow CELU
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
1 | 1 | 1 | 3 |
+8 more TTM periods Free account |
| 349.83% | 628.23% | 5,736.39% | (6,372.77%) | ||
| (62.45%) | (76.50%) | (66.41%) | (57.65%) | ||
ROIC |
(695.71%) | (1,070.92%) | (153.64%) | (172.59%) | |
Return on Tangible Assets |
734.06% | 726.09% | (3,220.71%) | (1,099.18%) | |
Average Days of Receivables |
91.99 | 63.97 | 60.31 | 91.29 | |
Free Cash Flow per Share |
(0.30) | (0.52) | (0.25) | (0.11) | |
Free Cash Flow |
(8.81) | (13.25) | (6.56) | (2.54) | |
| Other line items | |||||
Cash ROIC |
(141.89%) | (83.21%) | (32.81%) | (13.52%) | |
Accounts Receivable Turnover |
1.92 | 2.92 | 5.24 | 3.62 | |
Accounts Payable Turnover |
0.74 | 0.81 | 1.00 | 1.05 | |
Inventory Turnover |
5.39 | 6.71 | 6.14 | 5.47 | |
Average Days of Payables |
509.77 | 480.42 | 447.75 | 444.81 | |
Days of Inventory on Hand |
9.69 | 10.38 | 46.67 | 80.39 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
75.33% | 56.59% | 38.21% | 33.24% | |
Selling, General and Administrative Expense of Revenue |
243.38% | 193.09% | 128.79% | 124.70% | |
Share Based Compensation of Revenue |
47.36% | 39.09% | 24.81% | 23.99% | |
Interest Coverage |
(13.06) | (9.08) | (6.33) | (5.94) | |
Operating CF/Net income |
0.12 | 0.14 | 0.08 | 0.03 | |
Depreciation/Fixed assets |
0.13 | 0.13 | 0.13 | 0.13 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.65 | 1.04 | 1.54 | 1.86 | |
Operating CF per Share |
(0.30) | (0.52) | (0.25) | (0.11) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 1 Oct 2026